
We’re excited to share more about Indonesia’s NHI system! It’s incredible to see how they implemented universal healthcare and overcame unique challenges.
These insights are based on a recent interview by Alec Hogg and Ali Ghufron Mukti but through the lens of health economics and outcomes research, and access to medicines.
Of course, no system is perfect, and Indonesia’s NHI journey reminds us of the importance of constant vigilance to address challenges like funding and corruption issues.
Thank you for sharing these important lessons!
Recent Posts
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New Era in Cardiovascular...
The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes transcatheter aortic valve implantation (TAVI) in...
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Agonists
This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucagon-like peptide-1 (GLP-1) receptor agonists for ty...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future Directions
The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report detailing 104 positive recommendations for new hu...